InVision Medical Technology

InVision Medical Technology develops AI software for echocardiography, the most common cardiac imaging exam. Its products read the standard DICOM images an echo lab already produces, from GE, Philips, Siemens, Canon and handheld point of care scanners, and return measurements and disease assessments into the existing PACS, cardiovascular information system and Epic record, with no new hardware and no change to how images are acquired. Two products are FDA 510(k) cleared. Precision LVEF automates left ventricular ejection fraction measurement for adult patients and was evaluated in a blinded, randomized prospective trial published in Nature in 2023. Precision Cardiac Amyloid assesses features of cardiac amyloidosis across apical four chamber and parasternal long axis views in adults aged 65 and older, returning a risk assessment into the originating study; it previously held Breakthrough Device designation and was developed with support from Alexion, AstraZeneca Rare Disease. Precision Reporting, which drafts structured echo reports with 18 automated measurements written as editable report fields rather than pixels burned into the image, plus Precision Cirrhosis and Precision VHD, are in development. Deployment is on premises or in the vendor's validated cloud, data stays in the United States, and implementation takes about four weeks led by a named engineer. Pricing is not published and sales run through a briefing with the clinical and commercial teams. The vendor points to reimbursement instead: outpatient CPT Category III code 0932T, effective January 1, 2025, covers adjunctive AI analysis when LVEF is 50 percent or above, and CMS has approved an additional Medicare inpatient payment of up to $2,275 per eligible stay from October 1, 2026. The company was founded by the cardiologists and computer scientists who authored the underlying academic research over the past decade, and is backed by Y Combinator.